Shigella cells

Endolytix Technology, Inc is developing a new therapeutic approach that addresses one of the largest emerging problems in human health: antibiotic resistance

The Problem

According to the CDC:

Antibiotic resistance—the ability of germs to defeat the drugs designed to kill them—is one of the greatest global public health challenges of our time.

2.8 million antibiotic-resistant infections occur in the U.S. each year, 35,000 people die as a result.

For a history of antibiotic resistance go here.

The world is running out of antibiotics, read more here.

Our Solution

Endolytix provides options for patients who have few to none.

Endolytix is developing novel therapeutics to address the most resistant of antibiotic infections that are difficult to access, treat, and patient tolerance for current therapies are low.

Endolytix therapies are very effective at killing pathogenic bacteria including multi-drug resistant bacteria, not healthy normal flora.